← Back to Search

Behavioural Intervention

Physical Activity & Education for Obesity

N/A
Recruiting
Led By Jacob Kariuki, PhD, NP
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years
Be older than 18 years old
Must not have
History of cerebrovascular disease (CVD)
History of type 2 diabetes (T2D)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months after screening procedures start
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the PATH program, which offers online exercise routines featuring relatable individuals. It targets people with obesity who face barriers to physical activity. By showing similar people succeeding in exercise, the program aims to motivate participants and improve their health.

Who is the study for?
This trial is for adults over 18 with obesity (BMI ≥30kg/m2) who don't meet physical activity guidelines and have regular internet access. It's not for pregnant individuals, those in health-related litigation, or people needing supervised exercise due to conditions like stroke or diabetes.
What is being tested?
The study tests a program called PATH which uses peers similar in body size and fitness to encourage physical activities like walking, dancing, and toning exercises. Participants will also receive dietary education and use a physical activity tracker.
What are the potential side effects?
Since the interventions involve common physical activities and educational components, side effects are minimal but may include typical exercise-related discomforts such as muscle soreness or fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of stroke or brain blood flow problems.
Select...
I have been diagnosed with type 2 diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months after screening procedures start
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months after screening procedures start for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adherence to protocol procedures
Attainment of recruitment goal
Participants' satisfaction of protocol procedures (acceptability)
+1 more
Secondary study objectives
Changes in Monocyte Chemoattractant Protein-1 (MCP-1)
Changes in T2D risk score
Changes in adiponectin and leptin
+1 more
Other study objectives
Change in exercise self-efficacy questionnaire (EXSE)
Change in exercise self-regulation
Change in the Outcome Expectations for Exercise Scale questionnaires.
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: PATH InterventionExperimental Treatment3 Interventions
Insufficiently active adults with obesity will be assigned to the PATH intervention.
Group II: Control GroupExperimental Treatment3 Interventions
Insufficiently active adults with obesity will be assigned to the attention control group.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dietary education
2015
N/A
~70
PATH Intervention
2021
N/A
~80
Control Group
2012
Completed Phase 2
~2470

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The PATH program aims to increase physical activity among individuals with obesity by addressing psychological barriers such as stigma, shame, and low exercise self-efficacy, and by promoting enjoyable and less exhausting activities. This approach helps patients engage in regular PA, which improves cardiometabolic outcomes regardless of weight loss. Other common treatments for obesity include dietary changes to reduce caloric intake, pharmacotherapy to suppress appetite or inhibit fat absorption, and behavioral therapy to modify eating and activity habits. These treatments are crucial as they collectively improve physical health, enhance psychological well-being, and reduce the risk of obesity-related diseases.

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,444 Previous Clinical Trials
4,331,166 Total Patients Enrolled
468 Trials studying Obesity
589,655 Patients Enrolled for Obesity
Emory UniversityLead Sponsor
1,697 Previous Clinical Trials
2,603,868 Total Patients Enrolled
20 Trials studying Obesity
15,652 Patients Enrolled for Obesity
American Diabetes AssociationOTHER
143 Previous Clinical Trials
101,028 Total Patients Enrolled
24 Trials studying Obesity
1,617 Patients Enrolled for Obesity
~32 spots leftby Nov 2025